Resources
148 Results (showing 41 - 50)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 10/29/2020 (updated 4/3/2024)
Triumph over the opioid epidemic requires ALL traditional and non-traditional partners to come to the table. Join us to explore strategies for increasing the reach and sustainability of rural community coalitions by ensuring the right partners are at your table and can contribute to solving this crisis rather than be consumed by it.
Posted 10/23/2020 (updated 4/3/2024)
This report analyzes Medicaid State Drug Utilization Data from 2011 to 2018 to track Medicaid prescriptions, unit prices, and spending after accounting for federal rebates paid by manufactures to Medicaid programs for extended-release MOUDs.
Posted 10/23/2020 (updated 4/3/2024)
The objective of this report was to perform a systematic review of the beneficial and harmful effects of BUP-ER 100 mg and 300 mg for the management of moderate-to-severe OUD in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product.
Posted 10/23/2020 (updated 4/3/2024)
These pilot study results suggest comparable safety and effectiveness of unobserved and office induction and point toward utilization of non-inferiority design during future definitive protocol development.
Posted 10/23/2020 (updated 4/3/2024)
This article offers data regarding offering buprenorphine treatment at a public hospital primary care setting using a home, unobserved induction protocol.
Posted 10/23/2020 (updated 4/3/2024)
The goal of this module is to train providers to initiate patients on buprenorphine safely and effectively.
Posted 10/21/2020 (updated 4/3/2024)
This study sought to identify best practices for retaining individuals in treatment and for achieving continuity of care between settings.
Posted 9/1/2021 (updated 4/2/2024)
Posted 9/1/2021 (updated 4/2/2024)